title: DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient.
abstract: Parainfluenza virus (PIV) may cause life-threatening pneumonia in lung transplant patients and there are no proven effective therapies. We report the use of inhaled DAS181, a novel sialidase fusion protein, to treat severe PIV type 3 pneumonia in a lung transplant patient. Treatment was well tolerated and associated with improvement in oxygenation and symptoms, along with rapid clearance of PIV. DAS181 should be systematically evaluated for treatment of PIV infection in transplant recipients.
authors.affiliation: Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195-6175, USA.
authors.forename: D R
authors.initials: DR
authors.lastname: Drozd
authors.forename: A P
authors.initials: AP
authors.lastname: Limaye
authors.forename: R B
authors.initials: RB
authors.lastname: Moss
authors.forename: R L
authors.initials: RL
authors.lastname: Sanders
authors.forename: C
authors.initials: C
authors.lastname: Hansen
authors.forename: J D
authors.initials: JD
authors.lastname: Edelman
authors.forename: G
authors.initials: G
authors.lastname: Raghu
authors.forename: M
authors.initials: M
authors.lastname: Boeckh
authors.forename: R M
authors.initials: RM
authors.lastname: Rakita
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016040:Lung Transplantation / Q000009:adverse effects*; D008875:Middle Aged; D010224:Parainfluenza Virus 3, Human / Q000302:isolation & purification*; D011024:Pneumonia, Viral / Q000188:drug therapy* / Q000209:etiology; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D010253:Respirovirus Infections / Q000188:drug therapy* / Q000209:etiology; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D011993:Recombinant Fusion Proteins; C525612:oplunofusp